A phase i study of volasertib combined with afatinib, in advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 76, Issue 4, 2015, Pages 843-851

  Machiels, Jean Pascal ^a   Peeters, Marc ^b   Herremans, Catherine ^a   Surmont, Veerle ^c   Specenier, Pol ^b   De Smet, Marina ^d   Pilz, Korinna ^e,f   Strelkowa, Natalja ^e   Liu, Dan ^e   Rottey, Sylvie ^c  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d Boehringer Ingelheim   (Belgium)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^f ClinDevConsult GmbH   (Germany)

Author keywords

Advanced cancer; Afatinib; EGFR; Phase I trial; PLK; Volasertib

Indexed keywords

AFATINIB; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; VOLASERTIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PTERIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ABDOMINAL PAIN; ACNE; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CREATININE BLOOD LEVEL; DECREASED APPETITE; DERMATITIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; DRY SKIN; DYSGEUSIA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HYPOKALEMIA; INFECTION; INFLAMMATION; INOPERABLE CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MUCOSAL BLEEDING; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; NAUSEA; NEUTROPENIA; NEUTROPENIC INFECTION; PANCYTOPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; SIDE EFFECT; SINGLE DRUG DOSE; SKIN FISSURE; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; TREATMENT FAILURE; VOMITING; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG INTERACTION; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; MULTICENTER STUDY; NEOPLASMS; ORAL DRUG ADMINISTRATION; PATHOLOGY; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASMS; NEUTROPENIA; PROTEIN KINASE INHIBITORS; PTERIDINES; QUINAZOLINES; SEVERITY OF ILLNESS INDEX; THROMBOCYTOPENIA;

EID: 84942191834     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2860-2     Document Type: Article

References (27)

1. Schöffski P (2009) Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 14:559-570
2. Strebhardt K (2010) Multifaceted Polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 9:643-660
3. Takahashi T, Sano B, Nagata T, Kato H, Sugiyama Y, Kunieda K, Kimura M, Okano Y, Saji S (2003) Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 94:148-152
4. Wolf G, Elez R, Doermer A, Holtrich U, Ackermann H, Stutte HJ, Altmannsberger HM, Rübsamen-Waigmann H, Strebhardt K (1997) Prognostic significance of Polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 14:543-549
5. Medema RH, Lin CC, Yang JC (2011) Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC. Clin Cancer Res 17:6459-6466
6. Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J, Haslinger C, Garin-Chesa P, Adolf GR (2009) BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 15:3094-3102
7. Schöffski P, Awada A, Dumez H, Gil T, Bartholomeus S, Wolter P, Taton M, Fritsch H, Glomb P, Munzert G (2012) A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer 48:179-186
8. Stadler WM, Vaughn DJ, Sonpavde G, Vogelzang NJ, Tagawa ST, Petrylak DP, Rosen P, Lin CC, Mahoney J, Modi S, Lee P, Ernstoff MS, Su WC, Spira A, Pilz K, Vinisko R, Schloss C, Fritsch H, Zhao C, Carducci MA (2014) An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Cancer 120:976-982
9. Döhner H, Lübbert M, Fiedler W, Fouillard L, Haaland A, Brandwein JM, Lepretre S, Reman O, Turlure P, Ottmann OG, Müller-Tidow C, Krämer A, Raffoux E, Döhner K, Schlenk RF, Voss F, Taube T, Fritsch H, Maertens J (2014) Randomized, phase 2 trial comparing low-dose cytarabine with or without volasertib in AML patients not suitable for intensive induction therapy. Blood 124:1426-1433
10. Baselga J, Swain SM (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9:463-475
11. Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232
12. Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7:505-516
13. Woodburn JR (1999) The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82:241-250
14. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341-354
15. Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358:1160-1174
16. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich H, Wong KK (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27:4702-4711
17. Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, Kraemer O, Himmelsbach F, Haaksma E, Adolf GR (2012) Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 343:342-350
18. US Food and Drug Administration (2013) Gilotrif Prescribing Information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/201292s000lbl.pdf
19. Kang SH, Ahn CW (2002) An investigation of the traditional algorithm-based designs for phase 1 cancer trials. Drug Inf J 36:865-873
20. Common Terminology Criteria For Adverse Events (CTCAE) (2006) Cancer therapy evaluation program, common terminology criteria for adverse events. Version 3.0, DCTD, NCI, NIH, DHHS. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf
21. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
22. Lin C-C, Su W, Yen C-J, Hsu C-H, Su W-P, Yeh K-H, Lu Y-S, Cheng AL, Huang DC, Fritsch H, Voss F, Taube T, Yang JC (2014) A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous Polo-like kinase inhibitor, in patients with advanced solid malignancies. Br J Cancer 110:2434-2440
23. Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, Ang J, Temple G, Bell S, Shahidi M, Uttenreuther-Fischer M, Stopfer P, Futreal A, Calvert H, de Bono JS, Plummer R (2010) Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 28:3965-3972
24. Gordon MS, Mendelson DS, Gross M, Uttenreuther-Fischer M, Ould-Kaci M, Zhao Y, Stopfer P, Agus DB (2013) A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors. Invest New Drugs 31:409-416
25. Marshall J, Hwang J, Eskens FA, Burger H, Malik S, Uttenreuther-Fischer M, Stopfer P, Ould-Kaci M, Cohen RB, Lewis NL (2013) A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors. Invest New Drugs 31:399-408
26. Stopfer P, Marzin K, Narjes H, Gansser D, Shahidi M, Uttereuther-Fischer M, Ebner T (2012) Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother Pharmacol 69:1051-1061
27. Bouche O, Maindrault-Goebel F, Ducreux M, Lledo G, Andre T, Stopfer P, Amellal N, Merger M, De Gramont A (2011) Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer. Anticancer Res 31:2271-2281